Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

NCT00001249 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Leukemia, T-Cell
Lymphoma, T-Cell, Cutaneous

Interventions

DRUG: Yttrium-90 radiolabeled anti-Tac antibody

Sponsor

National Cancer Institute (NCI)